CIK 0001374690 · Non-accelerated filer<br>Smaller reporting company
Larimar Therapeutics, Inc.
Sign in to watch- Ticker
- LRMR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 203857670
- Phone
- 844-511-9056
- Business address
- THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA, 19004
- Former names
- ZAFGEN, INC., ZAFGEN INC
- Open-market buys, last 90 days
- $382,086
- in 7 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$382,086. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-27 | Hamilton Thomas Edward Director | Purchase | +100,000 | $5.00 | $500K | 664,798 |
| 2026-02-27 | THOMAS FRANK E Director | Purchase | +5,000 | $5.00 | $25K | 7,000 |
| 2026-02-27 | SHERMAN JEFFREY W Director | Purchase | +5,000 | $5.00 | $25K | 5,000 |
| 2026-01-26 | Shankar Gopi Chief Development Officer | Grant or award | +25,637 | 76,443 | ||
| 2026-01-26 | Shankar Gopi Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +153,822 | 153,822 | ||
| 2026-01-26 | Clayton Russell Chief Medical Officer | Grant or award | +25,637 | 71,443 | ||
| 2026-01-26 | Clayton Russell Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +153,822 | 153,822 | ||
| 2026-01-26 | BEN-MAIMON CAROLE President and CEO | Grant or award | +100,100 | 368,276 | ||
| 2026-01-26 | BEN-MAIMON CAROLE President and CEO | Grant or award · Stock Option (Right to Buy) | +600,600 | 600,600 | ||
| 2026-01-26 | Celano Michael Chief Financial Officer | Grant or award | +37,604 | 215,785 | ||
| 2026-01-26 | Celano Michael Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +225,622 | 225,622 | ||
| 2025-07-31 | Flynn James E Director | Purchase | +3,387,529 | $3.20 | $10.8M | 9,538,918 |
| 2025-07-31 | Flynn James E Director | Purchase | +3,387,539 | $3.20 | $10.8M | 9,538,945 |
| 2025-07-31 | Flynn James E Director | Purchase | +2,599,932 | $3.20 | $8.3M | 7,321,129 |
| 2025-05-13 | Flynn James E Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2025-05-13 | SHERMAN JEFFREY W Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2025-05-13 | Truitt Joseph Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2025-05-13 | Hamilton Thomas Edward Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2025-05-13 | THOMAS FRANK E Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 | ||
| 2025-05-13 | LEFF JONATHAN S Director | Grant or award · Stock Option (Right to Buy) | +19,000 | 19,000 |
Page 2 of 7 · 136 trades